Akston Biosciences Signs Licensing Agreement with Dechra Pharma for AKS-425c, a Once-a-Week Insulin Therapy for Cats

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for AKS-425c, a Once-a-Week Insulin Therapy for Cats

Akston Biosciences, which develops new classes of biologic therapeutics, today announced it has signed licensing, development and supply agreements with Dechra Pharmaceuticals PLC, a global veterinary pharmaceuticals company, for the commercialization of AKS-425c, a once-a-week insulin therapy for the treatment of diabetes in cats. Read more >>

Share this post